May 19 (Reuters) - Pfizer ( PFE ) has signed a licensing
agreement worth up to $6 billion with Chinese pharmaceutical
products developer 3SBio Inc ( TRSBF ) for the development,
manufacturing and commercialization of a drug undergoing trials
for treatment of certain types of cancer and tumours, the U.S.
drugmaker said on Monday.